Last reviewed · How we verify

Xianmin Song, MD — Portfolio Competitive Intelligence Brief

Xianmin Song, MD pipeline: 0 marketed, 0 filed, 0 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Akeso · 1 shared drug class
  2. Bio-Thera Solutions · 1 shared drug class
  3. Fujian Akeylink Biotechnology Co., Ltd. · 1 shared drug class
  4. Janssen Research & Development, LLC · 1 shared drug class
  5. Qilu Pharmaceutical Co., Ltd. · 1 shared drug class
  6. Shanghai JMT-Bio Inc. · 1 shared drug class
  7. Suzhou Suncadia Biopharmaceuticals Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Xianmin Song, MD:

Cite this brief

Drug Landscape (2026). Xianmin Song, MD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/xianmin-song-md. Accessed 2026-05-16.

Related